Shulov Innovative Science Ltd (SIS) is an advanced clinical-stage biopharmaceutical company focused on developing New Chemical Entities (NCE’s) for therapeutic as anti-inflammatory, anti-viral, and analgesic agents. The NCE’s are short synthetic peptides branded as ZEP-3 and ZEP-4, and both molecules possess the unique biological activity and potent therapeutic use for a wide range of clinical indications.

SIS completed a Phase II clinical study in Herpes Labialis (Cold sores) in 210 participants, with highly encouraging results in all endpoints, mainly in time to healing and time to relief as well as a clear decrease in Pain Intensity.

SIS completed a Phase I clinical study with the  ZEP-3 compound (in cream formulation), topically administered. The treatment was well tolerated, appears to be safe to use, and well an established skin pharmacokinetic profile. Therefore, this Phase I is suitable for several indications treated by topical application, such as Atopic Dermatitis, Burns, Psoriasis, and Herpes Zoster.

SIS is conducting a Phase II clinical study for Atopic Dermatitis (AD). The active substance, ZEP-3,  is not based on steroids, thus giving the Company a clear and unique advantage over the industry standard and other competitors in this indication.

SIS has started a Phase I/II study in Lung Inflammation and Phase II in Burns.

Moreover, SIS is developing additional clinical indications such as Herpes Zoster, Genital Herpes, Occular Herpes, and Psoriasis.